Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.7000 (0.56%) ($2.7000 - $2.7000) on Wed. Jan. 26, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.92% (three month average) | RSI | 30 | Latest Price | $2.7000(0.56%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.1% a day on average for past five trading days. | Weekly Trend | HTBX declines -6.9% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EEM(57%) VWO(56%) BLOK(55%) DRIV(53%) IPO(53%) | Factors Impacting HTBX price | HTBX will decline at least -1.96% in a week (0% probabilities). VXX(-49%) VIXM(-45%) UUP(-29%) BNDX(-6%) TLT(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.96% (StdDev 3.92%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-11.55(-527.78%) | Resistance Level | $3 | 5 Day Moving Average | $2.69(0.37%) | 10 Day Moving Average | $2.84(-4.93%) | 20 Day Moving Average | $3(-10%) | To recent high | -51.8% | To recent low | 8% | Market Cap | $297m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |